{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T22:52:19Z","timestamp":1781736739013,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Labex Revive","award":["ANR-10-LABX-73"],"award-info":[{"award-number":["ANR-10-LABX-73"]}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-23-CPJ1-0134-01"],"award-info":[{"award-number":["ANR-23-CPJ1-0134-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"crossref","award":["453989101"],"award-info":[{"award-number":["453989101"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100019125","name":"Sorbonne Universit\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019125","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CNRS"},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chimeric Antigen Receptor (CAR)-T cells therapy has revolutionized the treatment of hematological cancers and are currently redirected towards non-malignant diseases. If correction of the gene defect remains the cornerstone of the treatment of Duchenne Muscular Dystrophy (DMD), the disease-associated fibrosis can limit its efficacy. We thus assessed the effects of eliminating cardiac fibrosis of DMD by CAR-T cells targeting Fibroblast Activation Protein (FAP), a protein strongly expressed by activated fibroblasts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In vitro CAR-T cells expressing both FAP and a green fluorescent probe (GFP) were first co-cultured with FAP\u2009+\u2009of FAP- target cells to check for FAP-expressing lymphocyte activation. Then, anti-FAP CAR-T cells were intravenously delivered in a dystrophic murine model (D2.\n                      <jats:italic>mdx<\/jats:italic>\n                      ), following lymphodepletion, to investigate the kinetics, biodistribution, cardiac functional and anti-fibrotic effects of anti-FAP CAR-T cells compared with control lymphocytes engineered to only express GFP. The mechanism of action at a cellular level was assessed by single-cell RNA-sequencing of harvested hearts.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In vitro anti-FAP CAR-T cells were successfully activated when co-cultured with FAP\u2009+\u2009target cells. In a dystrophic murine model (D2.\n                      <jats:italic>mdx<\/jats:italic>\n                      ), anti-FAP CAR-T cells, intravenously delivered following lymphodepletion, homed to the heart and skeletal muscles, where they decreased FAP and fibrosis-associated genes. Single-cell RNA-sequencing linked these changes to a decrease in a definite cluster of fibrogenic fibroblasts. Concomitantly, anti-FAP CAR-T cells improved cardiac function compared to control mice injected with GFP-transduced T lymphocytes or bovine serum albumin used as negative controls.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results suggest that anti-FAP CAR-T cells could be efficient for mitigating fibrosis and thus complement gene therapy of DMD. More generally, their therapeutic benefits pave the way for potential applications extending to other fibrosis-associated diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13287-026-05025-1","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T04:45:21Z","timestamp":1777524321000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CAR-T cells targeting fibroblast activation protein eliminate pathological fibroblasts and preserve cardiac function in a Duchenne Muscular Dystrophy murine model"],"prefix":"10.1186","volume":"17","author":[{"given":"C\u00e9line","family":"Marigny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Revet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Boulch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Mougenot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenlin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Corre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9gane","family":"Lemaitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axelle","family":"Bois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Collombat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ara","family":"Parlakian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-C\u00e9cile","family":"Perier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Bot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Lafuste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Hagege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haig","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Cochain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Bousso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onnik","family":"Agbulut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Menasch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"5025_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s42255-022-00537-5","volume":"4","author":"H Aghajanian","year":"2022","unstructured":"Aghajanian H, Rurik JG, Epstein JA. CAR-based therapies: opportunities for immuno-medicine beyond cancer. Nat Metab. 2022;4:163\u20139. https:\/\/doi.org\/10.1038\/s42255-022-00537-5.","journal-title":"Nat Metab"},{"key":"5025_CR2","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1007\/s13346-023-01308-9","volume":"13","author":"S Shahvali","year":"2023","unstructured":"Shahvali S, Rahiman N, Jaafari MR, Arabi L. Targeting fibroblast activation protein (FAP): advances in CAR-T cell, antibody, and vaccine in cancer immunotherapy. Drug Deliv Transl Res. 2023;13:2041\u201356. https:\/\/doi.org\/10.1007\/s13346-023-01308-9.","journal-title":"Drug Deliv Transl Res"},{"key":"5025_CR3","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","volume":"573","author":"H Aghajanian","year":"2019","unstructured":"Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L, et al. Targeting cardiac fibrosis with engineered T cells. Nature. 2019;573:430\u20133. https:\/\/doi.org\/10.1038\/s41586-019-1546-z.","journal-title":"Nature"},{"key":"5025_CR4","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.121.263555","volume":"63","author":"J Diekmann","year":"2022","unstructured":"Diekmann J, Koenig T, Thackeray JT, Derlin T, Czerner C, Neuser J, et al. Cardiac fibroblast activation in patients early after acute myocardial infarction: integration with MR tissue characterization and subsequent functional outcome. J Nucl Med Off Publ Soc Nucl Med. 2022;63:1415\u201323. https:\/\/doi.org\/10.2967\/jnumed.121.263555.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"5025_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primer. 2021;7:1\u201319. https:\/\/doi.org\/10.1038\/s41572-021-00248-3.","journal-title":"Nat Rev Dis Primer"},{"key":"5025_CR6","doi-asserted-by":"publisher","first-page":"e135703","DOI":"10.1172\/jci.insight.135703","volume":"5","author":"DAG M\u00e1zala","year":"2020","unstructured":"M\u00e1zala DAG, Novak JS, Hogarth MW, Nearing M, Adusumalli P, Tully CB, et al. TGF-\u03b2\u2013driven muscle degeneration and failed regeneration underlie disease onset in a DMD mouse model. JCI Insight. 2020;5:e135703. https:\/\/doi.org\/10.1172\/jci.insight.135703.","journal-title":"JCI Insight."},{"key":"5025_CR7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00246-022-02989-8","volume":"44","author":"L James","year":"2023","unstructured":"James L, Menteer J, Moss LC, Durazo-Arvizu R, Wood JC, Ramos-Platt L, et al. Early-onset late gadolinium enhancement is a prognostic factor for Duchenne cardiomyopathy. Pediatr Cardiol. 2023;44:433\u201340. https:\/\/doi.org\/10.1007\/s00246-022-02989-8.","journal-title":"Pediatr Cardiol"},{"key":"5025_CR8","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00176-2023","author":"A Lechner","year":"2023","unstructured":"Lechner A, Herzig JJ, Kientsch JG, Kohler M, Bloch KE, Ulrich S, et al. Cardiomyopathy as cause of death in Duchenne muscular dystrophy: a longitudinal observational study. ERJ Open Res. 2023. https:\/\/doi.org\/10.1183\/23120541.00176-2023.","journal-title":"ERJ Open Res."},{"key":"5025_CR9","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1097\/NEN.0b013e3181aa31c2","volume":"68","author":"I Desguerre","year":"2009","unstructured":"Desguerre I, Mayer M, Leturcq F, Barbet J-P, Gherardi RK, Christov C. Endomysial fibrosis in duchenne muscular dystrophy: a marker of poor outcome associated with macrophage alternative activation. J Neuropathol Exp Neurol. 2009;68:762\u201373. https:\/\/doi.org\/10.1097\/NEN.0b013e3181aa31c2.","journal-title":"J Neuropathol Exp Neurol"},{"key":"5025_CR10","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/NEN.0b013e3181e9a34b","volume":"69","author":"L Zhou","year":"2010","unstructured":"Zhou L, Lu H. Targeting fibrosis in Duchenne muscular dystrophy. J Neuropathol Exp Neurol. 2010;69:771\u20136. https:\/\/doi.org\/10.1097\/NEN.0b013e3181e9a34b.","journal-title":"J Neuropathol Exp Neurol"},{"key":"5025_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2025.101545","author":"M Ferrand","year":"2025","unstructured":"Ferrand M, Rocca CJ, Corre G, Buffa V, Frin S, Garnache-Ottou F, et al. FAP-CAR-T cells reduce dystrophic muscle fibrosis, improving adeno-associated virus gene transfer efficacy. Mol Ther Methods Clin Dev. 2025. https:\/\/doi.org\/10.1016\/j.omtm.2025.101545.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"5025_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/hmg\/ddv460","volume":"25","author":"WD Coley","year":"2016","unstructured":"Coley WD, Bogdanik L, Vila MC, Yu Q, Van Der Meulen JH, Rayavarapu S, et al. Effect of genetic background on the dystrophic phenotype in mdx mice. Hum Mol Genet. 2016;25:130\u201345. https:\/\/doi.org\/10.1093\/hmg\/ddv460.","journal-title":"Hum Mol Genet"},{"key":"5025_CR13","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1172\/JCI39845","volume":"119","author":"A Heydemann","year":"2009","unstructured":"Heydemann A, Ceco E, Lim JE, Hadhazy M, Ryder P, Moran JL, et al. Latent TGF-\u03b2\u2013binding protein 4 modifies muscular dystrophy in mice. J Clin Invest. 2009;119:3703\u201312. https:\/\/doi.org\/10.1172\/JCI39845.","journal-title":"J Clin Invest"},{"key":"5025_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao Y, Stuart T, Kowalski MH, Choudhary S, Hoffman P, Hartman A, et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat Biotechnol. 2024;42:293\u2013304. https:\/\/doi.org\/10.1038\/s41587-023-01767-y.","journal-title":"Nat Biotechnol"},{"key":"5025_CR15","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics J Integr Biol. 2012;16:284\u20137. https:\/\/doi.org\/10.1089\/omi.2011.0118.","journal-title":"Omics J Integr Biol"},{"key":"5025_CR16","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8.","journal-title":"Genome Biol"},{"key":"5025_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/ITT.S439969","volume":"13","author":"Y Li","year":"2024","unstructured":"Li Y, Gu Y, Yang P, Wang Y, Yu X, Li Y, et al. CD69 is a promising immunotherapy and prognosis prediction target in cancer. ImmunoTargets Ther. 2024;13:1\u201314. https:\/\/doi.org\/10.2147\/ITT.S439969.","journal-title":"ImmunoTargets Ther"},{"key":"5025_CR18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/sj.cdd.4402244","volume":"15","author":"SP Cullen","year":"2008","unstructured":"Cullen SP, Martin SJ. Mechanisms of granule-dependent killing. Cell Death Differ. 2008;15:251\u201362. https:\/\/doi.org\/10.1038\/sj.cdd.4402244.","journal-title":"Cell Death Differ"},{"key":"5025_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00832-4","author":"SM Albelda","year":"2023","unstructured":"Albelda SM. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat Rev Clin Oncol. 2023. https:\/\/doi.org\/10.1038\/s41571-023-00832-4.","journal-title":"Nat Rev Clin Oncol"},{"key":"5025_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22:85\u201396. https:\/\/doi.org\/10.1038\/s41577-021-00547-6.","journal-title":"Nat Rev Immunol"},{"key":"5025_CR21","doi-asserted-by":"publisher","first-page":"11805","DOI":"10.3390\/ijms241411805","volume":"24","author":"D Giorgio","year":"2023","unstructured":"Giorgio D, Novelli D, Motta F, Cerrato M, Olivari D, Salama A, et al. Characterization of the cardiac structure and function of conscious D2B10-Dmdmdx\/J (D2-mdx) mice from 16\u201317 to 24\u201325 weeks of age. Int J Mol Sci. 2023;24:11805. https:\/\/doi.org\/10.3390\/ijms241411805.","journal-title":"Int J Mol Sci"},{"key":"5025_CR22","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s13059-018-1603-1","volume":"19","author":"M Stoeckius","year":"2018","unstructured":"Stoeckius M, Zheng S, Houck-Loomis B, Hao S, Yeung BZ, Mauck WM, et al. Cell Hashing with barcoded antibodies enables multiplexing and doublet detection for single cell genomics. Genome Biol. 2018;19:224. https:\/\/doi.org\/10.1186\/s13059-018-1603-1.","journal-title":"Genome Biol"},{"key":"5025_CR23","doi-asserted-by":"publisher","first-page":"12260","DOI":"10.1038\/ncomms12260","volume":"7","author":"O Kanisicak","year":"2016","unstructured":"Kanisicak O, Khalil H, Ivey MJ, Karch J, Maliken BD, Correll RN, et al. Genetic lineage tracing defines myofibroblast origin and function in the injured heart. Nat Commun. 2016;7:12260. https:\/\/doi.org\/10.1038\/ncomms12260.","journal-title":"Nat Commun"},{"key":"5025_CR24","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/s41586-021-03674-1","volume":"595","author":"M Alexanian","year":"2021","unstructured":"Alexanian M, Przytycki PF, Micheletti R, Padmanabhan A, Ye L, Travers JG, et al. A transcriptional switch governs fibroblast activation in heart disease. Nature. 2021;595:438\u201343. https:\/\/doi.org\/10.1038\/s41586-021-03674-1.","journal-title":"Nature"},{"key":"5025_CR25","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nm.1852","volume":"14","author":"C Gargioli","year":"2008","unstructured":"Gargioli C, Coletta M, De Grandis F, Cannata SM, Cossu G. PlGF-MMP-9-expressing cells restore microcirculation and efficacy of cell therapy in aged dystrophic muscle. Nat Med. 2008;14:973\u20138. https:\/\/doi.org\/10.1038\/nm.1852.","journal-title":"Nat Med"},{"key":"5025_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2025.101554","volume":"33","author":"M Ferrand","year":"2025","unstructured":"Ferrand M, Rocca CJ, Corre G, Buffa V, Frin S, Garnache-Ottou F, et al. FAP-CAR-T cells reduce dystrophic muscle fibrosis, improving adeno-associated virus gene transfer efficacy. Mol Ther Methods Clin Dev. 2025;33:101545. https:\/\/doi.org\/10.1016\/j.omtm.2025.101554.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"5025_CR27","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1152\/ajpcell.00196.2023","volume":"325","author":"F Mogharehabed","year":"2023","unstructured":"Mogharehabed F, Czubryt MP. The role of fibrosis in the pathophysiology of muscular dystrophy. Am J Physiol-Cell Physiol. 2023;325:1326\u201335. https:\/\/doi.org\/10.1152\/ajpcell.00196.2023.","journal-title":"Am J Physiol-Cell Physiol."},{"key":"5025_CR28","doi-asserted-by":"publisher","first-page":"1303935","DOI":"10.3389\/fimmu.2023.1303935","volume":"14","author":"B Lickefett","year":"2023","unstructured":"Lickefett B, Chu L, Ortiz-Maldonado V, Warmuth L, Barba P, Doglio M, et al. Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Front Immunol. 2023;14:1303935. https:\/\/doi.org\/10.3389\/fimmu.2023.1303935.","journal-title":"Front Immunol"},{"key":"5025_CR29","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","volume":"118","author":"RJ Brentjens","year":"2011","unstructured":"Brentjens RJ, Rivi\u00e8re I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118:4817\u201328. https:\/\/doi.org\/10.1182\/blood-2011-04-348540.","journal-title":"Blood"},{"key":"5025_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172666","volume":"863","author":"A Iqubal","year":"2019","unstructured":"Iqubal A, Sharma S, Ansari MA, Najmi AK, Syed MA, Ali J, et al. Nerolidol attenuates cyclophosphamide-induced cardiac inflammation, apoptosis and fibrosis in Swiss Albino mice. Eur J Pharmacol. 2019;863:172666. https:\/\/doi.org\/10.1016\/j.ejphar.2019.172666.","journal-title":"Eur J Pharmacol"},{"key":"5025_CR31","doi-asserted-by":"publisher","first-page":"9547","DOI":"10.1158\/0008-5472.CAN-05-1175","volume":"65","author":"L-X Wang","year":"2005","unstructured":"Wang L-X, Shu S, Plautz GE. Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells. Cancer Res. 2005;65:9547\u201354. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-1175.","journal-title":"Cancer Res"},{"key":"5025_CR32","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1093\/cvr\/cvad140","volume":"119","author":"B Kattih","year":"2023","unstructured":"Kattih B, Boeckling F, Shumliakivska M, Tombor L, Rasper T, Schmitz K, et al. Single-nuclear transcriptome profiling identifies persistent fibroblast activation in hypertrophic and failing human hearts of patients with longstanding disease. Cardiovasc Res. 2023;119:2550\u201362. https:\/\/doi.org\/10.1093\/cvr\/cvad140.","journal-title":"Cardiovasc Res"},{"key":"5025_CR33","doi-asserted-by":"publisher","first-page":"10978","DOI":"10.1073\/pnas.1204708109","volume":"109","author":"A Lorts","year":"2012","unstructured":"Lorts A, Schwanekamp JA, Baudino TA, McNally EM, Molkentin JD. Deletion of periostin reduces muscular dystrophy and fibrosis in mice by modulating the transforming growth factor-\u03b2 pathway. Proc Natl Acad Sci. 2012;109:10978\u201383. https:\/\/doi.org\/10.1073\/pnas.1204708109.","journal-title":"Proc Natl Acad Sci"},{"key":"5025_CR34","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1161\/CIRCRESAHA.124.325017","volume":"136","author":"S Yoshida","year":"2025","unstructured":"Yoshida S, Hayashi H, Kawahara T, Katsuki S, Kimura M, Hino R, et al. A vaccine against fibroblast activation protein improves murine cardiac fibrosis by preventing the accumulation of Myofibroblasts. Circ Res. 2025;136:26\u201340. https:\/\/doi.org\/10.1161\/CIRCRESAHA.124.325017.","journal-title":"Circ Res"},{"key":"5025_CR35","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1093\/cvr\/cvac142","volume":"118","author":"TA McKinsey","year":"2023","unstructured":"McKinsey TA, Foo R, Anene-Nzelu CG, Travers JG, Vagnozzi RJ, Weber N, et al. Emerging epigenetic therapies of cardiac fibrosis and remodelling in heart failure: from basic mechanisms to early clinical development. Cardiovasc Res. 2023;118:3482\u201398. https:\/\/doi.org\/10.1093\/cvr\/cvac142.","journal-title":"Cardiovasc Res"},{"key":"5025_CR36","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1038\/s41467-025-59093-7","volume":"16","author":"J Yan","year":"2025","unstructured":"Yan J, Wang SY, Su Q, Zou MW, Zhou ZY, Shou J, et al. Targeted immunotherapy rescues pulmonary fibrosis by reducing activated fibroblasts and regulating alveolar cell profile. Nat Commun. 2025;16:3748. https:\/\/doi.org\/10.1038\/s41467-025-59093-7.","journal-title":"Nat Commun"},{"key":"5025_CR37","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/cvr\/cvad104","volume":"119","author":"X Chen","year":"2023","unstructured":"Chen X, Li X, Wu X, Ding Y, Li Y, Zhou G, et al. Integrin beta-like 1 mediates fibroblast-cardiomyocyte crosstalk to promote cardiac fibrosis and hypertrophy. Cardiovasc Res. 2023;119:1928\u201341. https:\/\/doi.org\/10.1093\/cvr\/cvad104.","journal-title":"Cardiovasc Res"},{"key":"5025_CR38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1161\/CIRCRESAHA.120.318277","volume":"128","author":"LA Bradley","year":"2021","unstructured":"Bradley LA, Young A, Li H, Billcheck HO, Wolf MJ. Loss of endogenously cycling adult cardiomyocytes worsens myocardial function. Circ Res. 2021;128:155\u201368. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.318277.","journal-title":"Circ Res"},{"key":"5025_CR39","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1084\/jem.20130110","volume":"210","author":"E Tran","year":"2013","unstructured":"Tran E, Chinnasamy D, Yu Z, Morgan RA, Lee C-CR, Restifo NP, et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med. 2013;210:1125\u201335. https:\/\/doi.org\/10.1084\/jem.20130110.","journal-title":"J Exp Med"},{"key":"5025_CR40","doi-asserted-by":"publisher","DOI":"10.1101\/2025.02.25.640143","author":"CN Yashaswini","year":"2025","unstructured":"Yashaswini CN, Cogliati B, Qin T, To T, Williamson T, Papp TE, et al. In vivo anti-FAP CAR T therapy reduces fibrosis and restores liver homeostasis in metabolic dysfunction-associated steatohepatitis. BioRxiv Prepr Serv Biol. 2025. https:\/\/doi.org\/10.1101\/2025.02.25.640143.","journal-title":"BioRxiv Prepr Serv Biol."},{"key":"5025_CR41","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/965631","volume":"2014","author":"Y Kharraz","year":"2014","unstructured":"Kharraz Y, Guerra J, Pessina P, Serrano AL, Mu\u00f1oz-C\u00e1noves P. Understanding the process of fibrosis in Duchenne muscular dystrophy. BioMed Res Int. 2014;2014:965631. https:\/\/doi.org\/10.1155\/2014\/965631.","journal-title":"BioMed Res Int"},{"key":"5025_CR42","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik JG, Tomb\u00e1cz I, Yadegari A, M\u00e9ndez Fern\u00e1ndez PO, Shewale SV, Li L, et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375:91\u20136. https:\/\/doi.org\/10.1126\/science.abm0594.","journal-title":"Science"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-026-05025-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05025-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05025-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T22:25:24Z","timestamp":1781735124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13287-026-05025-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5025"],"URL":"https:\/\/doi.org\/10.1186\/s13287-026-05025-1","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"2 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures were performed in accordance with National and European legislations, under the license APAFIS #34549 (title of the approved project: Evaluation des CAR-T cells pour traiter la fibrose dans la Dystrophie Musculaire de Duchenne dans un mod\u00e8le murin; date of approval: 2022, December 7) (French Ministry of National Education, Higher Education and Research). DBA\/2J and D2.\n                      mdx\n                      (DBA\/2J background) mice were obtained from Charles Rivers and The Jackson Laboratory, respectively.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This project was partially funded by Capstan Therapeutics. J-A.E., P.M., Ad.B. and H.A. held equities in Capstan Therapeutics and Ad.B. and H.A were employees of Capstan before the company was acquired by Abbvie.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"222"}}